Chromadex is a Los Angeles-based bioscience company focused on developing proprietary ingredient technologies, including NAD+ research. It operates through Consumer Products, Ingredients, and Analytical Reference Standards segments, employing 106 staff since its IPO in 2007.
Niagen Bioscience (NAGE) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Niagen Bioscience's actual EPS was $0.09, beating the estimate of $0.02 per share, resulting in a 341.18% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
